Core Insights - Steris reported revenue of $1.48 billion for the quarter ended March 2025, reflecting a year-over-year increase of 4.3% and an EPS of $2.74, up from $2.41 in the same quarter last year [1] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.09%, while the EPS exceeded expectations by 5.79% [1] Financial Performance Metrics - Healthcare revenues reached $1.06 billion, surpassing the average estimate of $1.05 billion, marking a 4.9% increase year-over-year [4] - Healthcare Products - Consumables generated $352.74 million, slightly below the estimate of $355.87 million, but still showing a 6% increase from the previous year [4] - Healthcare Products - Capital equipment reported $318.03 million, which was below the average estimate of $329.58 million, representing a decline of 4.1% year-over-year [4] - Healthcare Products - Service revenues were $386.41 million, exceeding the estimate of $367.62 million, with a significant year-over-year increase of 12.5% [4] - Life Sciences revenues totaled $149.47 million, falling short of the $158.82 million estimate, reflecting a 7% decrease year-over-year [4] - Applied Sterilization Technologies (AST) revenues were $273.89 million, slightly above the estimate of $269.92 million, with a year-over-year increase of 9.2% [4] - Life Sciences - Service revenues were $36.45 million, below the estimate of $44.18 million, showing a decline of 20.7% year-over-year [4] - Life Sciences - Capital equipment revenues were $36.98 million, under the average estimate of $40.52 million, representing a decrease of 16.4% year-over-year [4] - Life Sciences - Consumables generated $76.04 million, slightly below the estimate of $77.15 million, with an 8% increase year-over-year [4] Operating Income - Operating income for Healthcare was reported at $279.71 million, exceeding the average estimate of $255.95 million [4] - Corporate and Other reported an operating loss of $99.31 million, worse than the estimated loss of $83.07 million [4] - Operating income for Applied Sterilization Technologies (AST) was $122.20 million, slightly above the average estimate of $118.69 million [4] Stock Performance - Steris shares have returned +4.6% over the past month, compared to the Zacks S&P 500 composite's +9.9% change, indicating potential for future outperformance [3]

Core Insights - Analysts project that Steris (STE) will report quarterly earnings of $2.58 per share, reflecting a 7.1% year-over-year increase, with revenues expected to reach $1.48 billion, a 4.2% increase from the same quarter last year [1] Revenue Projections - 'Revenues- Healthcare' are projected to be $1.05 billion, indicating a 4.5% increase year-over-year [4] - 'Revenues- Healthcare Products- Service' are expected to reach $360.96 million, suggesting a 5.1% year-over-year increase [4] - 'Revenues- Healthcare Products- Capital equipment' is estimated at $327.37 million, reflecting a 1.3% decrease from the prior-year quarter [4] - 'Revenues- Healthcare Products- Consumables' are projected at $364.74 million, indicating a 9.6% year-over-year increase [5] - 'Revenues- Applied Sterilization Technologies (AST)' are expected to be $269.92 million, reflecting a 7.6% increase from the year-ago quarter [5] - 'Revenues- Life Sciences' are projected to reach $155.49 million, indicating a 3.2% decrease year-over-year [5] - 'Revenues- Life Sciences- Service' is expected to be $41.39 million, reflecting a 10% decrease year-over-year [6] - 'Revenues- Life Sciences- Consumables' are projected at $80.04 million, indicating a 13.7% year-over-year increase [6] - 'Revenues- Life Sciences- Capital equipment' is expected to be $35.43 million, reflecting a 19.9% decrease year-over-year [6] Operating Income Estimates - The consensus estimate for 'Operating income / (loss)- Healthcare' is $255.95 million, compared to $245.22 million reported in the same quarter last year [7] - 'Operating income / (loss)- Applied Sterilization Technologies (AST)' is estimated at $118.69 million, compared to $114.22 million reported in the same quarter last year [7] - The consensus for 'Operating income / (loss)- Life Sciences' is projected at $64.54 million, slightly up from $64.49 million reported in the previous year [8] Stock Performance - Steris shares have increased by 4% over the past month, while the Zacks S&P 500 composite has moved up by 13.7% [9] - With a Zacks Rank 2 (Buy), Steris is expected to outperform the overall market performance in the near term [10]